Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...

Braun Stacey Associates cut its stake in Regeneron Pharmaceuticals by 4.5% during the first quarter, lowering its holdings to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Regeneron Pharmaceuticals, Inc.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

Pharmaceutical giant Regeneron won the court-approved auction in May, offering $256 million for 23andMe and its banks of customers' DNA and genetic data. Regeneron said it would use the 23andMe data ...

The company had previously selected a $256 million bid from Regeneron Pharmaceuticals as the lead offer. A representative from Regeneron did not immediately respond to a request for comment.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a ...